CD8+ CTLs efficiently recognize and destroy tumor cells, which expose peptides derived from tumor-associated antigens (TAAs) in the complex with human leukocyte antigen (HLA) class I molecules [12]. The gene discussed is CD8A; the disease is neoplasm.